#Denmark #Roche Diagnostics #Nordic Bioscience #PRO-C3 #Herlev

Nordic Bioscience Launches the PRO-C3 Test in Partnership with Roche Diagnostics

On May 8, 2025, Nordic Bioscience proudly announced the launch of its highly anticipated PRO-C3 test by Roche Diagnostics on the cobas analysers. The introduction of the Roche Elecsys® PRO-C3 test marks a significant milestone in the assessment of liver fibrosis severity, a critical condition that is responsible for approximately 4 million deaths annually worldwide.

Integrating the ADAPT formula, which factors in age, diabetes status, PRO-C3 levels, and platelet counts, the test provides healthcare providers with tools to make informed decisions regarding patient care. The PRO-C3 biomarker has been meticulously validated in Nordic Bioscience's CAP-CLIA certified laboratory based in Denmark, showcasing the company's commitment to precision medicine and the regulatory approval process necessary for clinical tools in diagnosis.

Nordic Bioscience has spent over a decade researching PRO-C3, resulting in the publication of more than 250 scientific papers focused on this biomarker and related fibrotic diseases. As the first biomarker from their fibrosis panel to receive CE approval, PRO-C3 aims to address the alarming statistic indicating that around 40% of deaths in the western world are linked to organ dysfunctions, particularly that of the liver. The tools developed by Nordic Bioscience help quantify liver health and provide vital information for patient management.

According to Morten Karsdal, CEO of Nordic Bioscience, “The Elecsys PRO-C3 test is the inaugural launch from our collaboration with Roche Diagnostics, and we take pride in making this advanced technology accessible globally to improve patient outcomes.” This strategic partnership not only expands the reach of the PRO-C3 biomarker but also emphasizes the significance of modern clinical chemistry in managing liver diseases.

The PRO-C3 test was previously available only through Nordic Bioscience's laboratory in Denmark. However, with Roche Diagnostics' involvement, it is now poised to reach an international audience, setting a new standard for liver fibrosis assessment. The Elecsys PRO-C3 test, developed under a license agreement between the two organizations, signifies a substantial leap forward in diagnostic methodologies aimed at effectively managing liver health.

Nordic Bioscience continues to innovate and lead in the field of biomarker development, harnessing its unique neoepitope technology. The company combines this expertise with preclinical and clinical research, enabling the delivery of biomarkers that facilitate swift and objective decision-making in clinical trials and diagnostics.

To learn more about the PRO-C3 test and its implications in liver health assessment, visit Nordic Bioscience’s website for comprehensive scientific and product information.

With ongoing initiatives and research driving advancements in healthcare, Nordic Bioscience maintains its commitment to improving patient lives through innovative diagnostic solutions.